Connect with us

Anti-Drug Agency

NDLEA Uncovers N22Billion Worth Of Tramadol Imported By Ukatu

Published

on

NDLEA Uncovers N22Billion Worth Of Tramadol Imported By Ukatu

NDLEA uncovers N22Billion worth of Tramadol imported by Ukatu

Olushola Okunlade Writes

The National Drug Law Enforcement Agency, NDLEA, has said that the ongoing investigation of a billionaire drug baron, Chief Afam Mallinson Ukatu, has led to the discovery of how the suspect imported into Nigeria in a single month, October 2019, two containers containing 1,284 cartons of Tramadol with a market value of over N22billion.

The Agency stated this in a statement on Tuesday 3rd May to counter insinuations by some hirelings that NDLEA has no evidence to pin a crime on Ukatu, who is the Chairman/CEO of Mallinson Group of companies.

Chief Afam Mallinson Ukatu
Chief Afam Mallinson Ukatu

After months of surveillance, Ukatu has eventually arrested on board a flight to Abuja at the MM2 terminal of the Lagos airport, Ikeja on Wednesday 13th April.

Investigations reveal he’s been a major importer of large consignments of different brands and high dosages of Tramadol Hydrochloride, ranging from 120mg, 200mg, 225mg, and 250mg, all of which are illicit. Ukatu owns pharmaceutical and plastic manufacturing companies, which he used as a cover to import illicit drugs into Nigeria.

The Agency said in the course of investigating the N3billion Tramadol saga between Ukatu and the Abba Kyari’s IRT team, its operatives have unearthed more evidence establishing how Ukatu has been importing large quantities of Tramadol far above the approved threshold allowed into the country.

In one instance, Ukatu through his Mallinson Group of companies imported into the country two-container loads of five different brands of Tramadol in October 2019 through the Apapa ports in Lagos. All the evidence so far gathered shows that the imported Tramadol brands were far above the threshold permitted to be imported into Nigeria.
No doubt the suspect will soon have his day in court

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.

Trending